News Jazz Pharmaceuticals plc

Equities

JAZZ

IE00B4Q5ZN47

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-23 pm EDT			5-day change	1st Jan Change
109.7 ^USD	+0.77%		+0.71%	-10.84%

Apr. 02	Jazz Pharmaceuticals Completes License Application for FDA for Biliary Tract Cancer Treatment	MT
Apr. 02	Jazz Pharmaceuticals Completes Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Jazz Pharmaceuticals to Report 2024 First Quarter Financial Results on May 1, 2024	Apr. 17	PR
Jazz Pharmaceuticals Completes License Application for FDA for Biliary Tract Cancer Treatment	Apr. 02	MT
Jazz Pharmaceuticals Completes Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer	Apr. 02	CI
JPMorgan Raises Jazz Pharmaceuticals' Price Target to $190 From $170, Maintains Overweight Rating	Mar. 25	MT
Piper Sandler Adjusts Price Target on Jazz Pharmaceuticals to $188 From $171, Maintains Overweight Rating	Mar. 20	MT
Jazz Pharmaceuticals : Zanidatamab R&D Day	Mar. 19	PU
Transcript : Jazz Pharmaceuticals plc - Special Call	Mar. 19
Stifel Raises Jazz Pharmaceuticals' Price Target to $230 From $225, Maintains Buy Rating	Mar. 15	MT
H.C. Wainwright Cuts Price Target on Jazz Pharmaceuticals to $200 From $204, Maintains Buy Rating	Mar. 14	MT
Jazz Pharmaceuticals to Host Virtual Zanidatamab R&D Day on Tuesday, March 19, 2024	Mar. 12	PR
Transcript : Jazz Pharmaceuticals plc Presents at Leerink Partners Global Biopharma Conference 2024, Mar-11-2024 02:00 PM	Mar. 11
Agrify Corp Stock Presents Compelling Opportunity As Deal Flow Intensifies ($AGFY)	Mar. 07	AQ
Transcript : Jazz Pharmaceuticals plc Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-04-2024 10:30 AM	Mar. 04
Jazz Pharmaceuticals : Corporate Overview	Mar. 01	PU
UBS Adjusts Jazz Pharmaceuticals Price Target to $131 From $135, Maintains Neutral Rating	Mar. 01	MT
Barclays Cuts Price Target on Jazz Pharmaceuticals to $230 From $235, Maintains Overweight Rating	Mar. 01	MT
Needham Cuts Price Target on Jazz Pharmaceuticals to $220 From $225, Maintains Buy Rating	Feb. 29	MT
Tranche Update on Jazz Pharmaceuticals plc's Equity Buyback Plan announced on November 8, 2016.	Feb. 28	CI
Jazz: Q4 Earnings Snapshot	Feb. 28	AQ
Jazz Pharmaceuticals Swings to Q4 Non-GAAP Earnings, Revenue Rises; 2024 Guidance Set, Shares Down After Hours	Feb. 28	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Jazz Pharmaceuticals plc

Equities

JAZZ

IE00B4Q5ZN47

Summary

Filters